John Buscombe, UK
Prof. Andrew Scott is Director, Department of Molecular Imaging and Therapy, Austin Health; Laboratory Head at the Olivia Newton-John Cancer Research Institute; and Professor of Medicine, University of Melbourne, and La Trobe University. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, and in molecular imaging, particularly oncology applications in PET in staging cancer, as well as global issues of nuclear medicine and human health. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies. He has over 360 peer reviewed publications, and numerous grants from National and International funding bodies.
He is the current President of the World Federation of Nuclear Medicine and Biology, and is on the Board of many significant organisations including the Australian Nuclear Science and Technology Organisation (ANSTO), Chair of the board of Cancer Trials Australia, member of the Scientific Committee of ARTnet, and Chair of the International Relations Committee of the Australian and New Zealand Society of Nuclear Medicine. He is also a Fellow of the Royal Australasian College of Physicians, Fellow of the Australian Academy of Health and Medical Sciences, Fellow of the Australian Institute of Company Directors, and in 2017 was awarded Member (AM) in the General Division of the Order of Australia.
Prof. Scott has published 320 peer reviewed papers and 21 book chapters, principally in the areas of oncology and molecular imaging. He has been the Principal Investigator of research grants from NHMRC, US National Institutes of Health, Australian Cancer Research Foundation, Cancer Council Victoria, Harry J Lloyd Foundation, Komen Foundation, Movember, Prostate Cancer Foundation of Australia, Cure Brain Cancer Foundation, Victorian Cancer Agency, and the Australian Government.
Marcel P.M. Stokkel, MD, PhD
Nuclear Medicine Physician at the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; head of the department of Nuclear Medicine and head of the division of Diagnostic Oncology. Chair of the Dutch Society of Nuclear Medicine. Research appointment at the University Medical Centre Utrecht (UMCU), The Netherlands.
Focus of research is imaging and treatment of Neuro-endocrine tumors (in collaboration with the UMC Utrecht), breast cancer, thyroid cancer and prostate cancer. Reviewer of many scientific journals and (co-) author of more than 200 papers in highly esteemed journals. Co-supervisor of many PhD programs and PI of several studies related to the afore mentioned topics of research.
Trainer in Radiology and Nuclear Medicine in the Netherlands. Invited speaker on behalf of the IAEA in many countries worldwide. Involved in many training programs in the Netherlands, including Radiology, Pulmonology and Endocrinology.
Professor of biophysics and nuclear medicine at University P & M Curie (Paris VI) since 1990, Head of the nuclear medicine department of University hospital Tenon from 1991 until 2018, Expert at the French Medicine Agency (AFSSAPS then ANSM and HAS) since 1992, Chairman of the Scientific Advisory Group “Diagnostic agents” of the European Medicines Evaluation Agency (EMEA), External expert for IAEA and European Commission
Medicine Doctor : 20/10/1978 (University P & M. Curie, Paris). Silver medal., Specialist in nuclear medicine in 1979, Specialist in endocrinology in 1982, Graduate in statistics and methodology of assays in 1978 (Pr Schwartz), Life Science Doctor (PhD) in 1989 (Université P&M Curie, Paris)
Clinical investigation on the role of PET in oncology, endocrinology and infectious diseases. Preclinical Micro PET imaging,
SCIENTIFIC SOCIETIES :
Member of the French Society of Nuclear Medicine (SFMNIM) former member of its board, Former chief editor of the French journal of Nuclear Medicine, Current member of the Editorial Board of the European Journal of Nuclear Medicine and Molecular Imaging, of the Italian and of the Spanish Journals of Nuclear Medicine, Member of the European Association of Nuclear Medicine (EANM), former French National Delegate and member of its board, former chairman of the EANM Task Group “Risk explanation”, Former member of the board of the European School of Nuclear Medicine (ESNM)
Former member of the Society for Nuclear Medicine (SNM) and of the Academy of Molecular Imaging (AMI)
Member of the French Society of Endocrinology
One complete book “Scintigraphie” (Masson publisher), One CD-ROM on FDG CDET, 11 Chapters of books, 46 lectures or review articles, Over 150 original articles referenced in Pub Med
H Hirsch factor = 36.
Dr. med. Marilena Theodorou
Consultant in Radiation Oncology
Studies: Medicine University of Leipzig, Germany
Specialty: Specialisation in Radiation Oncology and Radiotherapy, Klinikum Rechts der Isar, Technical University of Munich, Germany
Specialization: Specialization in Radiosurgery and Stereotactic High Precision Radiation
Specialization in Intensity Modulated Radiotherapy (IMRT) and Image Guidance Radiotherapy (IGRT)
Doctor Thesis (PhD): Tumor shrinkage assessed by volumetric MRI in the follow up after Radiosurgery and Stereotactic Radiotherapy of meningeomas. (Prof. Grosu and Prof. Molls) Technical University of Munich, Germany
Research interest: Brain tumors, Head Neck tumors, Lung- and Liver tumors, Prostate cancer
Stereotactic high Precision Radiotherapy (Cranial and extracranial stereotactic radiation)
IMRT / IGRT, Tomotherapy , PET-Plan in the radiation treatment plan
1st Award for the research work for brain radiosurgery and stereotactic radiation therapy, high precision radiation for brain tumors June 2014
DEGRO (German Association for Radiation Therapy and Radiooncology)
EANO (European association of neuro-oncology) Executive Board member 2018-2022
ESTRO (European Society for Radiotherapy and Oncology)
NOA (Neurooncology work team in Germany)
DKG (German caner society)
APRO (German work team for paediatrics tumors)
German work team for Radiosurgery/Stereotactic Radiation
German work team for brain tumors
PROS (paediatric radiotherapy oncology society
-Lead Consultant and Professor in Nuclear Medicine- Royal Liverpool University Hospital -1998 till date
-Immediate Past President of British Nuclear Medicine Society
-Editor in Chief of Nuclear Medicine Communications
-Chairman GM South Research Ethics Committee
-Member of Administration of Radioactive Substances Advisory Committee of UK Department of Health
-Member of Joint Specialty Committee on Nuclear Medicine of Royal college of Physicians of London
Irene Virgolini was appointed as a University lecturer (venia docendi ) for Experimental Nuclear Medicine in 1992 with her work on functional liver scintigraphy and then 1995 in Internal Medicine (venia docendi) with her work on oncological receptor scintigraphy at the Medical University of Vienna. In 2000, Virgolini became the Director of the Institute of Nuclear Medicine at the Vienna City Hospital Lainz. In 2003, she was appointed Director of the University Clinic of Nuclear Medicine at the Medical University of Innsbruck and became the Full Professor of Nuclear Medicine. Since then the further expansion of the Innsbruck University Clinic for Nuclear Medicine in Clinic, Research and Teaching has taken place. Since 2018 Virgolini also works as a Councillor for the Medical University of Vienna.
Irene Virgolini's focus in clinical research lies in the development and preclinical validation of new radiopharmaceuticals for Nuclear Medicine for diagnosis and therapy. Under the lead of Virgolini several new Nuclear Medicine tracer procedures have been clinically established. The Nuclear Medicine Department of the Medical University Innsbruck is involved in national and international co-operation, including the participation in expert committees as well as in scientific projects of the IAEA, both in preclinical development and in the clinical application of radiopharmaceuticals both for diagnosis and therapy. Virgolini`s work is also concerned with the patient-related "quality of life" within the scope of individualized high-dose therapy. Her clinical work and recent research has focused on the treatment of metastasized prostate cancer.
Virgolini has published more than 200 papers, her total impact factor is around 1000, the Hirsch Index 35 (based on Web of Science). She presented more than 300 lectures on the topics of molecular imaging and therapy worldwide. In 2018 Virgolini became the President of the international society WARMTH (World Association of Radiopharmaceutical Therapy).
Arturo Chiti graduated in Medicine and Surgery at the University of Milan and entered the Training Program in Nuclear Medicine, where he got his certification in 1993.
In the same year, he started working as Associate Chief at the National Cancer Institute in Milan, where he began his clinic and scientific experience in Oncology.
In 1997, he got the European Board of Nuclear Medicine fellowship.
In June 2000, he was called to lead the Nuclear Medicine Department at the Humanitas hospital in Milan.
On March 1, 2015, he was appointed Full Professor in Diagnostic Imaging and Radiotherapy at the Humanitas University in Milan, where he is also elected member of the Board.
He is the Director of the Department of the Biomedical Sciences at Humanitas University, where he also is Director of the Training Program in Radiology.
He is member of the Technical and Scientific Committee of the National Centre for Oncologic Adrotherapy in Italy (CNAO).
He is Editor in Chief of the European Journal of Nuclear Medicine and Molecular Imaging
He is a well-known invited speaker at numerous international congresses and conferences.
Arturo Chiti was the President 2015-16 of the European Association of Nuclear Medicine, where he was active since more than 10 years.
Since many years he is also acting as an expert consultant for International Atomic Energy Agency.
He is member of the European Cancer Organization (ECCO) Board and of the International Commission on Radiation Units and Measurements (ICRU).
He was awarded the honorary membership of the European Society for Therapeutic Radiology and Oncology in 2011.
Dr Constantinides qualified from University College London Medical School and gained his surgical membership in 2007. He completed a Doctorate of Medicine in 2009 at Imperial College and underwent another 6 years of Higher Surgical Training in London gaining the FRCS in General and Endocrine Surgery.
He sub-specialised in Endocrine Surgery for 3½ years at Hammersmith Hospital in London, the largest and pre-eminent centre in the UK, under Mr Fausto Palazzo and Mr Neil Tolley. He has expertise in all aspects of the specialty including minimally invasive, re-operative cases, functional neck dissections and en-block resections for metastatic thyroid & adrenal cancer respectively.
Dr Constantinides has published widely in scientific journals, presented at numerous international meetings and is a reviewer for international journals. He has also been a faculty member in several post – graduate and medical student courses and teaches regularly in medical schools both in Cyprus and the UK.
Since 2014, Dr Constantinides has formed his own Endocrine Surgery unit at ‘Evangelistria Medical Centre’ in Nicosia, Cyprus. The unit is currently operating across all fields of the specialty with special emphasis on thyroid cancer with over 200 resections and lymph node clearances performed annually.
Johannes Czernin, MD, Professor and Vice Chair
Department of Molecular and Medical Pharmacology
Chief Ahmanson Translational Imaging Division
David Geffen School of Medicine, UCLA
Johannes Czernin has 30 years of experience in nuclear medicine and molecular imaging. He is a Professor of Molecular and Medical Pharmacology in the David Geffen School of Medicine at UCLA and serves as the Chief of the Ahmanson Translational Imaging Division. His work focuses on improving the outcomes of cancer patients by developing novel diagnostic and therapeutic approaches. The major focus of his research team is the development of a translational theranostics program and the identification of effective combination between radioligand therapies and pharmacologic approaches. The current focus is prostate cancer to improve the results of radionuclide (radioligand) therapies that requires an understanding of resistance mechanisms that limit the effectiveness of theranostic approaches. He has published more than 250 manuscripts and currently serves as the Editor in Chief of the Journal of Nuclear.
Dr. Panayiotis Economides, MD, PhD, FACE, ECNU obtained his medical degree at the National and Kapodistrian University of Athens. He did his internship and residency in Internal Medicine at Newton-Wellesley Hospital/Tufts University School of Medicine followed by a fellowship in Endocrinology, Diabetes and Metabolism at the Beth Israel Deaconess Medical Center/ Joslin Diabetes Center and Harvard Medical School in Boston, Massachusetts. Before moving to Cyprus he was Staff Attending Physician and Instructor in Medicine at Harvard Medical School. In Cyprus he established the Nicosia Endocrinology Center, a referral center specializing in clinical and diagnostic thyroidology.
Evanthia Giannoula was born in Larisa, Greece on 2 March 1986. She graduated from the School of Medicine - School of Health Sciences, Aristotle University of Thessaloniki (AUTH) in Greece and received her Degree in Medical Studies in 2010. In 2015 she obtained her Masters Degree in Primary Health Care from the School of Medicine of the University of Thessaly (UTH) in Greece. In 2016 she started her PhD Thesis, entitled “Assessment of quality and safety environment provided by nuclear medicine departments services and assessment of quality of life in patients with malignant thyroid neoplasms” from AUTH. During the period between 2011 and 2017 she performed her residency in Nuclear Medicine in the Nuclear Medicine Department of Theagenion Cancer Hospital of Thessaloniki, practicing in all diagnostic and therapeutic procedures of Nuclear Medicine. During this period she also practiced in Oncology, Radiology and Cardiology as part of her residency, in the same Hospital. She received her title of medical specialization following the successful passing of examinations. Since the latter years of her residency until today she has been receiving specialized training in PET/CT imaging in PET/CT Department of Theagenion Cancer Hospital. Her main topic of research is the diagnostic and therapeutic management of thyroid malignant neoplasms and neuroendocrine tumors. During her MSc thesis she started studying the evaluation of health care quality and performing quality of life research. Today as a PhD candidate her research focuses on embracing these topics in order to ensure both prognosis and quality of life for patients. She has been member of research groups including MetroMRT Programme – Metrology for molecular radiation therapy, a part of the European Metrology Research Programme and an International phase IV field study for the reliability and validity of the EORTC Thyroid Cancer Module THY34. She has published part of her work in leading international journals such as European Journal of Nuclear Medicine and Molecular Imaging and Clinical Nuclear Medicine Journal as well as book chapters. She is also in the Editorial Board of Hellenic Journal of Nuclear Medicine and journal reviewer in several international journals. She participated as author in several projects that have been announced in National and International Conferences, where she has also been invited to give talks.
Dr. Ioannis Iakovou is associate Professor of Aristotle University of Thessaloniki. responsible for the therapeutic department of Nuclear Medicine at PAPAGEORGIOU hospital, training physicians in therapeutic nuclear medicine and following up many patients on outpatient basis per year. The most common treatments carried out concern thyroid disorders, radioimmunotherapy in lymphomas, treatment of painful bone metastatic disease, radiosynoviorthesis of joints with arthritis, radiopeptide therapy of neuroendocrine tumours and selective internal radiotherapy of liver metastatic disease.
He graduated from the Medical school of Aristotle Univeristy of Thessaloniki and specially educated in University of Pisa, Universitätsklinikum des Saarlandes, Hombourg, and in Nuclear Medicine Department of Valais Hospital in Sion / Swiss. He has an MBA in “Healthcare Management”
He is member Thyroid Committee in EANM, member of the board of Hellenic Society of Nuclear Medicine & Molecular Imaging, secretary of the Hellenic society of salivary glands and has been the vice president of Hellenic Society of Nuclear Medicine of Thessaloniki from 2009 to 2011. He is member of the editorial board of the “World Journal of Nuclear Medicine”, the “Hellenic Journal of Nuclear Medicine” and the “European Journal of Hybrid Imaging”.
He has co-authored over 50 scientific articles and books, and presented over 100 lectures at international conferences.
He also works as a National Representative in UEMS being also responsible of the continuing education of Hellenic society of Nuclear Medicine and Molecular Imaging.
John Buscombe was trained at the London Hospital Medical College graduating in 1984, after house posts in Southend, Essex, we trained in general internal medicine in Newham, London and mid Essex. He trained in Nuclear Medicine at the Middlesex Hospital under Profs Williams and Ell and at Guys Hospital under Prof Maisey and Fogelman. He was appointed to his first Consultant Post in Nuclear Medicine at the Medway Hospitals, Kent in 1992, The Royal Free Hospital, London in 1994 and Cambridge University Hospitals in 2010. He has had a long standing interest in SPECT, infection imaging, breast cancer imaging, theragnostics especially in NETs. At the Royal Free Hospital he set up the UK’s busiest radionuclide therapy unit. Since being in Cambridge his main research interests have been in the PET imaging of atheroma and looking at the aetiology of lung inflammation. He has published over 200 scientific papers and edited/authored 7 books.
He has a long standing interest in education writing 3 versions of the UK nuclear medicine curriculum, was chair of the FEBNM examination committee and has been a Professor of Nuclear Medicine at the University of Pretoria since 2010. In March 2018 he reduced his working hours when he became the President of the British Nuclear Medicine Society
Professor Richard P. Baum is Chairman and Clinical Director of the THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology at Zentralklinik Bad Berka (ENETS Center of Excellence since 2011).In 1997 he performed the first peptide receptor radiotherapy (PRRT) in Germany at the University Medical Center of Frankfurt/Main, where he holds a position as Professor of Nuclear Medicine since 1996.In 1989 he was elected as President of the International Research Group in Immunoscintigraphy and Immunotherapy (IRIST). He received numerous awards for his research in radiolabeled monoclonal antibodies and peptides (among others the Mallinckrodt Award of the German Society of Nuclear Medicine in 1989, the Sharabai Memorial Oration Award of the SNM India in 1996, the 2010 F.Y. Khoo Medal by the Singapore Radiological Society, and the Agasthiar Award by the SNMI in 2011). In 2011 he organized the First Theranostics World Congress (on Ga-68 and PRRT) with the topic “On The Way to Personalized Medicine” with 400 participants from 56 countries at Zentralklinik Bad Berka. In early 2013, his team performed the first worldwide Lu-177 PSMA radioligand therapy (PRLT) in a patient with metastatic prostate cancer. Since then over 1000 PRLTs have been administered. In the same year, he was re-elected IRIST President and also became President of the World Association of Radionuclide and Molecular Therapy (WARMTH). In 2014, he was honored by the NET Patients Support Group in Germany with the GLORINET Award. The ESMO made him Faculty Member for CUP/Endocrine Tumors in 2017. In June 2017 he presented the Henry N. Wagner, Jr. Lecture at the Opening Ceremony of the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging in Denver. Professor Baum has published >300 original papers in peer-reviewed journals, edited 4 books (including a handbook on Therapeutic Nuclear Medicine) and has lectured extensively.
Additional Honors/Awards in the last 5 years:
2012 Visiting Professor, Medical University Nanjing, China, Xi’an, Beograd
2013 Co-chair, Second Theranostics World Congress, Chandigarh, India
2015 Co-chair, Third Theranostics World Congress, Baltimore, Ml, USA
2015 Honorary Member of the Cuban Society of Oncology, Radiotherapy and Nuclear Medicine
2016 Member of the Publication Committee of the SNMMI
2015 Appointment as Board Member of the Therapy Center of Excellence of the SNMMI
2016 Appointment as Member of the Publication Committee of the SNMMI
2016 Editors’ Choice Award The Journal of Nuclear Medicine for the best clinical article in 2015 (68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015;56:1169-76)
2016 Co-Chair, Fourth Theranostics World Congress, Melbourne, Australia
2017 Appointment by the European Society for Medical Oncology (ESMO) as Faculty Member for the CUP, Endocrine Tumours and Others for the period 2017-2018
2017 Re-election as Board Member of the Therapy Center of Excellence of the SNMMI
2017 Visiting Professor invitation to McGill University, Montreal, Quebec
2018 Key Note Speaker, Taiwanese Society of Nuclear Medicine, Taipei, Taiwan
2018 Chairman Oncology Track, World Federation of Nuclear Medicine & Biology (WFNMB) Congress, Melbourne, Australia
Agathoclis Agathocleous was born in Nicosia in 1973. He is Consultant in Haematology at the Bank of Cyprus Oncology Centre in Nicosia. He obtained his medical degree from the University of Patras, Greece, Medical School in 1999. Dr Agathocleous was trained in internal medicine in Athens, Greece, and subsequently in Haematology at the Haematology and Lymphomas Department – Bone Marrow Transplantation Unit of the Evaggelismos General Hospital in Athens. He was trained in both malignant and non-malignant Haematology diseases. However, he had the opportunity to exhibit a special interest in Lymphomas, Leukemias, Myelomas and Bone Marrow Transplantation, since these are his special clinical interests.
After completing his training in Athens, he received a grant from the Bank of Cyprus Oncology Centre and joined the Department of Medical Oncology of the St. Bartholomew’s Hospital in London as Honorary Clinical Assistant in Haematology for almost a year. Apart from his a clinical post there, he also run a multicenter clinical trial as a sub-investigator, and got involved in a few other trials, that established his interest in the clinical trials field.
After his return to Cyprus he was employed at the post he currently has. As being the only Bank of Cyprus Oncology Centre Haematologist, he deals with all the Lymphomas, Multiple Myeloma cases and Myeloproliferative Neoplasms that are referred to the Centre, and also deals with the haematological complications or secondary heamatological malignancies of the Centre’s solidary tumors patients.
He is a founding member of the Cyprus Haematology Society and currently member of its Board. He is also an active member of the Hellenic Society of Haematology.
Dr Pushan Bharadwaj graduated as a medical doctor in Kolkata, India in 1990 and has been working as a full-time consultant for nearly 20 years with a total experience of more than 25 years in the specialty after post-graduation. After obtaining his Board Certification in Nuclear Medicine from the National Board of Examinations in India in 1996, he went to the United Kingdom for further training and obtained the Certificate of Completion of Specialist Training in Nuclear Medicine in 2001. He trained at the Royal Brompton and Royal Marsden Hospitals apart from brief stints at the St Bartholomew’s and University College of London Hospitals. He served the National Health Service, UK till 2011 as a consultant physician. He became a fellow of the Royal College of Physicians of Edinburgh in 2006. He was awarded the Diplomate of the Certification Board of Nuclear Cardiology, USA in 2007 and the Fellowship of the European Board of Nuclear Medicine in 2009. He is also a Certified Clinical Densitometrist by the International Society of Clinical Densitometry, USA. He has a special interest in cardiac imaging and also obtained a Master’s degree in Cardiology from the University of Brighton, UK. He has contributed many book chapters in the field of Nuclear Cardiology including one titled Nuclear Medicine in Heart failure in the Oxford Textbook of Heart Failure published in 2011. He has been working at the Singapore General Hospital since September 2015. He is married with two daughters and is keen on nature and heritage related activities.
Dr. Iulia Andreea Chiriac was born in the beautiful wine area of Vrancea county, Romania in Focșani on the 4th July 1987. She graduated from the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania and received her Degree in Medical Studies in 2012. During the period between 2013 and 2016 she performed her residency in Nuclear Medicine in the Nuclear Medicine Department of “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest and in the Compartment of Endocrinology - Radionuclide Therapy of “C.I. Parhon” National Institute of Endocrinology, Bucharest (2015- and continues to work here), focusing on diagnostic and radionuclide therapy procedures for oncology and endocrinology, in particular 131I therapy for thyroid cancer and hyperthyroidism.
She is one of the BIOMAT-ENDO database members - a project designed to be a platform to store all the main data regarding the patients with thyroid cancer hospitalized in the National Institute of Endocrinology (from the first hospitalization and continue with the periods of radioiodine therapy and follow-up).
She is a member of several European and Romanian association, participating in training courses, conferences and fellowship organized by EANM, ESMIT, IAEA, ESHI and ESR. Since 2015 she is the Secretary for the Romanian Society of Nuclear Medicine and Molecular Imaging and a member of organizing committee of the Romanian Society of Nuclear Medicine Conference (2015-2017). She became a Certified Ultrasonographer in 2016 and started her second residency in Radiology and Medical Imaging in 2017.
Professor Wim Oyen is nuclear medicine physician at the Department of Radiology and Nuclear Medicine of Rijnstate Hospital, Arnhem, The Netherlands and full Professor of Diagnostic Imaging and Radiotherapy at Humanitas University in Milan, Italy. From 2015-2018, he was full Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital, London, UK. Before working in the UK, he was a nuclear medicine physician and full Professor of Nuclear Medicine at the Radboud University Medical Centre Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine, Member of the Board of the Medical Staff and Director of the Research Institute for Oncology of RadboudUMC.
Professor Oyen’s main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 650 original science and review articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (Board Member, past-Congress Chair and EANM President as of 2019) and the International Cancer Imaging Society (President 2017/2018). Professor Oyen is a member of several Editorial Boards, including the European Journal of Nuclear Medicine and Molecular Imaging and the Journal of Nuclear Medicine.
Hossein Jadvar is past president and fellow of both Society of Nuclear Medicine and Molecular imaging (SNMMI) and American College of Nuclear Medicine (ACNM). He is a tenured Associate Professor of Radiology at University of Southern California (USC) Keck School of Medicine in Los Angeles with joint appointment as Associate Professor of Biomedical Engineering in Viterbi School of Engineering. He was a Visiting Scientist at California Institute of Technology. He received the BS in chemical engineering from Iowa State University (1982), MS in biomedical engineering from University of Wisconsin, Madison (1984), M.S. in computer engineering (1986) and PhD (1988) in bioengineering, both from University of Michigan, Ann Arbor, the MD degree from University of Chicago (1993), MPH from Harvard University (2005), and Executive MBA from USC (2007). His post-graduate medical education included an internship in internal medicine at UCSF (1993-94), diagnostic radiology and nuclear medicine residency at Stanford University (1994-98), and fellowship in PET at Harvard Medical School (1998-99). Dr. Jadvar is on leadership editorial boards of JNM, EJNMMI, CNM, AJR, MIB, Radiology, and many other journals. He has received several awards including SNMMI Tetalman Young Investigator Award, Western Regional SNMMI Distinguished Scientist Award, Academy of Radiology Research Distinguished Investigator Award, Ajit Padhy Memorial Award from WARMTH, and Best Mentor Awards from USC and ACNM. He is an NIH funded investigator, and serves on multiple NIH and DOD review panels, and is an IAEA expert in nuclear medicine. He has written more than 130 peer-reviewed journal articles, published 3 books, 30 book chapters, 9 patents, and has had more than 200 invited speaker presentations and visiting professorships at national and international venues. His research interests include applications of PET in clinical outcome research and in interdisciplinary translational molecular imaging research with particular current interest in prostate cancer, and theragnostics. (http://www-hsc.usc.edu/~jadvar)
As a nuclear medicine physician, he is interested in brain studies and radionanomedicine. In the past, he was involved in nuclear cardiology, brain mapping and molecular imaging sequentially in his carrier since he started nuclear medicine in 1990 as assistant professor in Seoul National University and Seoul National University Hospital, Korea. Finally he came to study brain connectivity using PET/MRI which are based on topological interpretation of the group PET and individual resting-state MRI. Recently, moving from molecular imaging to nanomedicine and theranostics, he just published a book by Springer, ‘Radionanomedicine; combined nuclear and nanomedicine’. He says that radionanomedicine is the way how nanomedicines (nanodrugs or nanomaterials) can enter into the clinical discipline. As theranostics are the future of nuclear medicine, our entire field moving from hybrid imaging to the nuclear theranostics, he held the TWC2019 (Theranostics World Congress 2019) in March 2019 in Jeju, Korea and started to take the role of President of World Federation of Nuclear Medicine and Biology during 2019-2020. He is now also the Vice-President of International Society for Nanomedicine.
Demetris Papamichael is Director of Medical Oncology at the Bank of Cyprus Oncology Centre in Nicosia, a post he has held since 1999. He obtained his medical degree from Charing Cross and Westminster Medical School, University of London in 1988. Dr Papamichael trained in internal medicine and obtained his Membership of the Royal Colleges of Physicians (MRCP) in 1992. His subsequent training in Medical Oncology was completed at the Royal Marsden and St Bartholomew’s Hospitals in London. He became a Fellow of the Royal College (FRCP) in 2002. Dr Papamichael is an American Society of Clinical Oncology (ASCO) Merit Award winner. He is an active researcher and has participated in a number of Industry sponsored studies as well as clinical trials coordinated by the European Organization for Research and Treatment of Cancer and the UK Medical Research Council/National Cancer Research Institute.
Dr Papamichael’s main clinical interests include gastrointestinal cancer, and cancer in the elderly. He has published his work in a number of peer-reviewed international journals. He is a member of ASCO, the European Society of Medical Oncology (ESMO), and the International Society of Geriatric Oncology (SIOG). Recently he headed a Task Force responsible for developing recommendations for the management colorectal cancer in the elderly under the auspices of SIOG. He is a member of the ESMO metastatic colorectal cancer guidelines committee, the ESMO GI faculty and co-chairman of the ESMO-SIOG working group. Dr Papamichael is actively involved in the organization and teaching of courses run by the European School of Oncology (ESO) and ESMO.
Dr Jelena Šaponjski
Born in Belgrade, 18th of June 1991
· 2010 - Park Hill South High School, Parkvile, USA
· 2016 - Faculty of Medicine, University of Belgrade. GPA 9,38
· 2017 – Resident in Nuclear medicine, Center for Nuclear Medicine, Clinical Center of Serbia
· From 2017 ongoing - PhD studies in a field of Radiology and Nuclear Medicine
· 2018 - Academic specialist in Nuclear Medicine, topic - „FDG PET/CT in detection of infection and inflammation of cardiovascular system“
Areas of interest:
Endocrinology, radionuclide therapy, oncology, PET/CT, infections and inflammations
· 2011- 2016- Ministry of science, education and technological development of Serbia- 5 scholarships for best students
· Three awards for the best student paper “Rising stars program 2016”, “Rising stars program 2017” and “Rising stars program 2018”, European Congresses of Radiology (ECR), Vienna, Austria, 2016, 2017, 2018.
Several training courses and fellowship organized by IAEA, EANM, ESMIT and ESHI
· 2018 - Member of organizing committee “Serbian Congress of Nuclear Medicine with international participation – 60 years of Nuclear Medicine in Serbia”
English and German
· 1996. – 2018. Folklore dancer
Author or coauthor of 5 papers in extenso in the journals cited in JCR base (IF-10,8) 2 papers in extenso in the journals cited in Pubmed, 10 papers presented in international and national meetings published as abstracts.